The cardiac marker testing market size has grown rapidly in recent years. It will grow from $7.19 billion in 2025 to $7.93 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to limited availability of high-sensitivity cardiac marker tests, reliance on centralized laboratory testing, growing prevalence of cardiovascular diseases, increasing awareness among healthcare providers, conventional manual diagnostic practices.
The cardiac marker testing market size is expected to see rapid growth in the next few years. It will grow to $11.61 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to development of automated and portable cardiac marker testing devices, rising adoption of point-of-care diagnostics, integration with digital health platforms, growing geriatric population and cardiovascular risk, advancements in reagent and kit sensitivity. Major trends in the forecast period include rising adoption of high-sensitivity cardiac biomarker tests, expansion of point-of-care testing facilities, integration of automated analyzers and immunoassay systems, growing use of cardiac marker testing in preventive cardiology, increasing demand for portable diagnostic devices.
The rising incidence of cardiovascular diseases is anticipated to support the expansion of the cardiac marker testing market going forward. Cardiovascular diseases include disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increasing occurrence of cardiovascular diseases is associated with unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, and air pollution. Cardiac marker testing plays a vital role in diagnosing cardiovascular conditions, assessing disease severity, and monitoring treatment response by detecting biomarkers released during myocardial injury. For example, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4% rise compared to the previous year. As a result, the rising incidence of cardiovascular diseases is strengthening demand within the cardiac marker testing market.
Leading companies operating in the cardiac marker testing market are focusing on developing technologically advanced products, such as cardiac assays, to deliver accurate and clinically valuable insights into heart health and function. Cardiac assays are diagnostic tests that measure specific biomarkers in blood or other samples to assess cardiac function, diagnose cardiovascular diseases, and evaluate heart-related risk. For example, in October 2023, Mindray, a China-based medical device company, launched its high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarker assays. The hs-cTnI assay demonstrates high sensitivity, precision, and reliability, achieving a 93% detection rate between the limit of detection and the 99th percentile upper reference limit, with an imprecision coefficient of variation below 5%. The NT-proBNP assay delivers high precision with a coefficient of variation of ≤5% while minimizing interference from common cardiovascular medications, supporting accurate heart failure diagnosis and management.
In August 2024, VION Biosciences, a US-based life sciences platform company, acquired Ansh Labs for an undisclosed amount. Through this acquisition, VION Biosciences aims to strengthen its footprint in the diagnostics sector, integrate advanced technologies, and expand its immunoassay development offerings. Ansh Labs is a US-based biotechnology company.
Major companies operating in the cardiac marker testing market are F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, Guangzhou Wondfo Biotech Co. Ltd., Randox Laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Alere Inc., Nano‑Ditech Corporation, Ortho Clinical Diagnostics, QuidelOrtho Corporation, DiaSorin S.p.A., PerkinElmer Inc., Meso Scale Diagnostics LLC, Boditech Med Inc., Response Biomedical Corp.
North America was the largest region in the cardiac marker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac marker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac marker testing market by increasing the cost of imported reagents, kits, and diagnostic instruments. Segments such as high-sensitivity troponin test kits and automated analyzers are particularly impacted, with regions like Asia-Pacific and Europe experiencing supply chain challenges and higher operational costs. While tariffs have posed cost pressures, they also encourage local manufacturing, innovation in reagent formulations, and investment in domestic production of diagnostic instruments, thereby strengthening regional capabilities.
The cardiac marker testing market research report is one of a series of new reports that provides cardiac marker testing market statistics, including cardiac marker testing industry global market size, regional shares, competitors with a cardiac marker testing market share, detailed cardiac marker testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker testing industry. This cardiac marker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac marker testing involves diagnostic tests that measure specific substances in the blood that indicate stress or damage to the heart. These markers, often proteins or enzymes, are released into the bloodstream when heart muscle is injured and are essential for diagnosing and evaluating conditions such as heart attacks, heart failure, and other cardiac diseases.
The key cardiac marker testing products include reagents, kits, and instruments. Reagents and kits are critical components in cardiac marker testing, containing the required chemicals and materials to conduct diagnostic evaluations. These tests measure biomarkers such as troponin I and T, creatine kinase-MB (CK-MB), natriuretic peptides, myoglobin, high-sensitivity C-reactive protein, and others, and are used in laboratory testing facilities, point-of-care testing sites, and academic institutions.
The cardiac marker testing market consists of revenues earned by entities by providing services such as homocysteine testing, cardiac stress testing, genetic testing for cardiovascular risk, remote monitoring and telemedicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac marker testing market also includes sales of lipoprotein(a) test kits, cardiac biomarker panels, point-of-care testing devices and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiac marker testing market size is expected to see rapid growth in the next few years. It will grow to $11.61 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to development of automated and portable cardiac marker testing devices, rising adoption of point-of-care diagnostics, integration with digital health platforms, growing geriatric population and cardiovascular risk, advancements in reagent and kit sensitivity. Major trends in the forecast period include rising adoption of high-sensitivity cardiac biomarker tests, expansion of point-of-care testing facilities, integration of automated analyzers and immunoassay systems, growing use of cardiac marker testing in preventive cardiology, increasing demand for portable diagnostic devices.
The rising incidence of cardiovascular diseases is anticipated to support the expansion of the cardiac marker testing market going forward. Cardiovascular diseases include disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increasing occurrence of cardiovascular diseases is associated with unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, and air pollution. Cardiac marker testing plays a vital role in diagnosing cardiovascular conditions, assessing disease severity, and monitoring treatment response by detecting biomarkers released during myocardial injury. For example, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4% rise compared to the previous year. As a result, the rising incidence of cardiovascular diseases is strengthening demand within the cardiac marker testing market.
Leading companies operating in the cardiac marker testing market are focusing on developing technologically advanced products, such as cardiac assays, to deliver accurate and clinically valuable insights into heart health and function. Cardiac assays are diagnostic tests that measure specific biomarkers in blood or other samples to assess cardiac function, diagnose cardiovascular diseases, and evaluate heart-related risk. For example, in October 2023, Mindray, a China-based medical device company, launched its high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarker assays. The hs-cTnI assay demonstrates high sensitivity, precision, and reliability, achieving a 93% detection rate between the limit of detection and the 99th percentile upper reference limit, with an imprecision coefficient of variation below 5%. The NT-proBNP assay delivers high precision with a coefficient of variation of ≤5% while minimizing interference from common cardiovascular medications, supporting accurate heart failure diagnosis and management.
In August 2024, VION Biosciences, a US-based life sciences platform company, acquired Ansh Labs for an undisclosed amount. Through this acquisition, VION Biosciences aims to strengthen its footprint in the diagnostics sector, integrate advanced technologies, and expand its immunoassay development offerings. Ansh Labs is a US-based biotechnology company.
Major companies operating in the cardiac marker testing market are F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, Guangzhou Wondfo Biotech Co. Ltd., Randox Laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Alere Inc., Nano‑Ditech Corporation, Ortho Clinical Diagnostics, QuidelOrtho Corporation, DiaSorin S.p.A., PerkinElmer Inc., Meso Scale Diagnostics LLC, Boditech Med Inc., Response Biomedical Corp.
North America was the largest region in the cardiac marker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac marker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac marker testing market by increasing the cost of imported reagents, kits, and diagnostic instruments. Segments such as high-sensitivity troponin test kits and automated analyzers are particularly impacted, with regions like Asia-Pacific and Europe experiencing supply chain challenges and higher operational costs. While tariffs have posed cost pressures, they also encourage local manufacturing, innovation in reagent formulations, and investment in domestic production of diagnostic instruments, thereby strengthening regional capabilities.
The cardiac marker testing market research report is one of a series of new reports that provides cardiac marker testing market statistics, including cardiac marker testing industry global market size, regional shares, competitors with a cardiac marker testing market share, detailed cardiac marker testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker testing industry. This cardiac marker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac marker testing involves diagnostic tests that measure specific substances in the blood that indicate stress or damage to the heart. These markers, often proteins or enzymes, are released into the bloodstream when heart muscle is injured and are essential for diagnosing and evaluating conditions such as heart attacks, heart failure, and other cardiac diseases.
The key cardiac marker testing products include reagents, kits, and instruments. Reagents and kits are critical components in cardiac marker testing, containing the required chemicals and materials to conduct diagnostic evaluations. These tests measure biomarkers such as troponin I and T, creatine kinase-MB (CK-MB), natriuretic peptides, myoglobin, high-sensitivity C-reactive protein, and others, and are used in laboratory testing facilities, point-of-care testing sites, and academic institutions.
The cardiac marker testing market consists of revenues earned by entities by providing services such as homocysteine testing, cardiac stress testing, genetic testing for cardiovascular risk, remote monitoring and telemedicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac marker testing market also includes sales of lipoprotein(a) test kits, cardiac biomarker panels, point-of-care testing devices and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiac Marker Testing Market Characteristics
3. Cardiac Marker Testing Market Supply Chain Analysis
4. Global Cardiac Marker Testing Market Trends and Strategies
5. Cardiac Marker Testing Market Analysis of End Use Industries
7. Global Cardiac Marker Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiac Marker Testing Total Addressable Market (TAM) Analysis for the Market
9. Cardiac Marker Testing Market Segmentation
10. Cardiac Marker Testing Market Regional and Country Analysis
11. Asia-Pacific Cardiac Marker Testing Market
12. China Cardiac Marker Testing Market
13. India Cardiac Marker Testing Market
14. Japan Cardiac Marker Testing Market
15. Australia Cardiac Marker Testing Market
16. Indonesia Cardiac Marker Testing Market
17. South Korea Cardiac Marker Testing Market
18. Taiwan Cardiac Marker Testing Market
19. South East Asia Cardiac Marker Testing Market
20. Western Europe Cardiac Marker Testing Market
21. UK Cardiac Marker Testing Market
22. Germany Cardiac Marker Testing Market
23. France Cardiac Marker Testing Market
24. Italy Cardiac Marker Testing Market
25. Spain Cardiac Marker Testing Market
26. Eastern Europe Cardiac Marker Testing Market
27. Russia Cardiac Marker Testing Market
28. North America Cardiac Marker Testing Market
29. USA Cardiac Marker Testing Market
30. Canada Cardiac Marker Testing Market
31. South America Cardiac Marker Testing Market
32. Brazil Cardiac Marker Testing Market
33. Middle East Cardiac Marker Testing Market
34. Africa Cardiac Marker Testing Market
36. Cardiac Marker Testing Market Competitive Landscape and Company Profiles
37. Cardiac Marker Testing Market Other Major and Innovative Companies
40. Cardiac Marker Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cardiac Marker Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiac marker testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiac marker testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac marker testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Reagents And Kits; Instruments2) By Biomarker Type: Troponin I And T; Creatine Kinase-MB (CK-MB); Natriuretic Peptide; Myoglobin; High-Sensitivity C-Reactive Protein; Other Biomarker Types
3) By Application: Laboratory Testing Facilities; Point-Of-Care Testing Facilities; Academic Institutions
Subsegments:
1) By Reagents and Kits: Troponin Test Kits; B-type Natriuretic Peptide (BNP) Test Kits; Creatine Kinase-MB (CK-MB) Test Kits; Myoglobin Test Kits; Other Cardiac Biomarker Reagents2) By Instruments: Point-Of-Care Testing Devices; Automated Analyzers; Immunoassay Systems; Portable Diagnostic Devices
Companies Mentioned: F. Hoffmann‑La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; Laboratory Corporation of America Holdings; Quest Diagnostics Inc.; Tosoh Corporation; Guangzhou Wondfo Biotech Co. Ltd.; Randox Laboratories Ltd.; Getein Biotech Inc.; Fujirebio Inc.; Mayo Clinic Laboratories; Alere Inc.; Nano‑Ditech Corporation; Ortho Clinical Diagnostics; QuidelOrtho Corporation; DiaSorin S.p.A.; PerkinElmer Inc.; Meso Scale Diagnostics LLC; Boditech Med Inc.; Response Biomedical Corp.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiac Marker Testing market report include:- F. Hoffmann‑La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG
- Laboratory Corporation of America Holdings
- Quest Diagnostics Inc.
- Tosoh Corporation
- Guangzhou Wondfo Biotech Co. Ltd.
- Randox Laboratories Ltd.
- Getein Biotech Inc.
- Fujirebio Inc.
- Mayo Clinic Laboratories
- Alere Inc.
- Nano‑Ditech Corporation
- Ortho Clinical Diagnostics
- QuidelOrtho Corporation
- DiaSorin S.p.A.
- PerkinElmer Inc.
- Meso Scale Diagnostics LLC
- Boditech Med Inc.
- Response Biomedical Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.93 Billion |
| Forecasted Market Value ( USD | $ 11.61 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
